	US 11,707,487 B2
	EpCAM antibody and CAR-T cells
Huan Yang, Millbury, MA (US); Moonsoo Jin, New York, NY (US); and Janusz Puc, Sudbury, MA (US)
Assigned to AffyImmune Therapeutics, Inc., Natick, MA (US)
Filed by Affyimmune Therapeutics, Inc., Natick, MA (US)
Filed on Apr. 13, 2021, as Appl. No. 17/228,844.
Claims priority of provisional application 63/009,018, filed on Apr. 13, 2020.
Prior Publication US 2021/0317229 A1, Oct. 14, 2021
Int. Cl. A61K 35/17 (2015.01); C07K 16/30 (2006.01); C07K 14/725 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01); C12N 5/10 (2006.01); C07K 16/46 (2006.01); C07K 14/705 (2006.01)

CPC A61K 35/17 (2013.01) [A61K 39/001166 (2018.08); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/30 (2013.01); C07K 16/46 (2013.01); C12N 5/10 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/73 (2013.01); C07K 2319/03 (2013.01)]

13 Claims

1. An antibody or an antigen-binding fragment thereof that binds to Ep-CAM comprising a light chain variable region (VL) and a heavy chain variable region (VH), wherein the VL CDR1, CDR2, and CDR3 have the amino acid sequences of SEQ ID NOs: 12, 13, and 14, respectively; the VH CDR1 and CDR2 have the amino acid sequences of SEQ ID NOs: 10 and 11, respectively; and the VH CDR3 region has the amino acid sequence of SEQ ID NO: 6, 7, 8, 3, 5, or 9.